ヒアルロン酸は何から作られていますか?

ヒアルロン酸is also known as hyaluronic acid. It is a viscous polysaccharide composed of (1-3)-2-acetamido-2-deoxy-β-D-glucose units linked by β-1,4 and β-1,3 glycosidic bonds, alternately connected with (1-4)-O-β-D-glucuronic acid units. Hyaluronic acid is a widely distributed polysaccharide molecule in nature that forms a viscoelastic substance when combined with water. In the human body, it is primarily found in skin and connective tissues, serving as an extracellular matrix. In addition to providing cells with water and volume, it possesses properties such as tissue stability, strong binding capacity, high viscoelasticity, weak species and tissue specificity, and lack of immunogenicity. Hyaluronic acid has widespread applications in drug delivery, anti-adhesion in orthopaedic surgery, cardiology, arthritis, cancer therapy, ophthalmology, and food supplements.

1ヒアルロン酸の準備

1.1動物組織抽出法

1934年、米国コロンビア大学の眼科教授マイヤーらは、牛の目のガラスのようなユーモアからこの物質を初めて単離した[1]。1970年代、balazsらはニワトリの櫛やヒトのへその緒からヒアルロン酸を抽出した[1]。

のmain process for extracting hyaluronic acid powder from animal tissues includes dehydration, grinding, soaking, extraction, purification, precipitation, and separation. The specific process is as follows: first, homogenise the tissue, then extract it with water and dilute salt solution. The extract is precipitated with chlorinated hexadecylpyridine or hexadecyl trimethylammonium bromide, The resulting precipitate is dissolved, the residue is removed, and the solution is precipitated with 2–3 times the volume of ethanol to obtain crude hyaluronic acid. Purification can be achieved by treating the crude product with ethanol or quaternary ammonium salts, or by further removing impurities and proteins using enzymatic hydrolysis, ultrafiltration, or ion exchange techniques, ultimately yielding the final product.

The tissue extraction method has the advantages of a simple process, high molecular weight, high viscosity, and strong moisturising properties. However, due to limitations in raw material availability and the coexistence of hyaluronic acid with other polysaccharides such as chondroitin sulfate in biological tissues, this method has low yield, poor separation, complex process, and high cost, making it unsuitable for large-scale production. It is more suitable for small-scale production with dispersed raw material sources. With the continuous increase in demand and application scope of hyaluronic acid, the animal tissue extraction method will inevitably be gradually replaced by other methods.

1.2微生物発酵法

1970年代から、研究者たちは微生物発酵を利用してヒアルロン酸パウダーを製造し始めました。日本の資生堂は、1985年にストレプトコッカス・エクイ(streptococcus equi)によるヒアルロン酸生産を初めて報告した。一般的に報告されているヒアルロン酸産生細菌は、主にbergey &に記載されているstreptococcus属のa群とc群である#39;s Manual. The A group mainly includes Streptococcus pyogenes, which are pathogenic to humans and unsuitable as production strains; the C group of Streptococcus species are non-pathogenic to humans and more suitable for industrial production. In recent years, foreign countries have already achieved industrial-scale production of hyaluronic acid using C group Streptococcus species [2].

Operational process: Inoculate the slant culture into conical flasks containing culture medium, incubate at 37°C for 12–16 hours, then transfer to seed tanks. The nitrogen source in the culture medium is peptone, beef extract, yeast extract, etc., the carbon source is glucose, and the inoculation ratio is 1:10. The fermentation broth formulation is essentially the same as the seed broth, except that the glucose content is higher, typically 3%–6%. Maintain an aeration rate of 0.3–1.0 vvm (volume of air per minute relative to the fermentation volume), stir at 120 rpm, and ferment at 37°C for 40–46 hours. During fermentation, adjust the pH to 6.5–7.0. In the later stages of fermentation, when the glucose concentration drops below 0.5% and the pH decreases slowly or stops decreasing, fermentation is complete. After fermentation, adjust the pH to 4.0–4.5 with trichloroacetic acid, filter to remove the bacterial mass, adjust the filtrate pH to 6.0–6.5, add 95% ethanol, and precipitate hyaluronic acid. Dissolve the precipitate in a 0.1 mol/L sodium chloride solution, stirring, add an excess of 1% CPC to form a complex precipitate with the hyaluronic acid in the filtrate, let stand, siphon off the mother liquor, wash the precipitate twice, dissolve in 0.4 mol/L sodium chloride solution with stirring overnight, filter, precipitate with ethanol, dehydrate with ethanol, and vacuum dry to obtain hyaluronic acid.

Currently, the fermentation method for producing hyaluronic acid as an alternative to tissue extraction has become a trend. The fermentation method for producing hyaluronic acid has a simple process, does not rely on animal tissues, and its yield is not limited by raw material sources. Additionally, hyaluronic acid exists in a free state in the fermentation broth, making it easy to separate, purify, and industrialise. Therefore, the fermentation method has become the primary method for industrial production of hyaluronic acid [3].

1.3人工合成法

Related studies have shown that hyaluronic acid in living organisms is synthesised by hyaluronic acid synthase catalysing the reaction of UDP-G1cA and UDP-G1cNAc [4]. Therefore, researchers both domestically and internationally have attempted to synthesise hyaluronic acid in vitro using enzymatic methods and have made some progress. Neuman [5] reported a method for the artificial synthesis of hyaluronic acid, First, a polysaccharide polymer, one of the biological macromolecules, is used to synthesise hyaluronic acid oxazepane derivatives. Then, a decomposing enzyme (hyaluronidase from sheep or cow testes) is added to form a complex of the derivative and the enzyme. Finally, the enzyme is removed from the reaction solution, and hyaluronic acid is synthesised. Additionally, precipitation, separation, and purification are required.

Artificially synthesised hyaluronic acid is similar in quality to natural hyaluronic acid, but the precursor materials required for in vitro synthesis are expensive, so the artificial synthesis method is generally used for producing high-molecular-weight, high-purity hyaluronic acid [6].

2ヒアルロン酸誘導体の研究

Clinical applications have demonstrated that natural hyaluronic acid possesses excellent biocompatibility; however, it is easily degraded and diffused in tissues, resulting in short retention times in the body and suboptimal application outcomes. Recent studies have shown that hyaluronic acid derivatives obtained through modification and cross-linking can address these limitations [7].

The hydroxyl, carboxyl, N-acetylamino, and reducing ends of the hyaluronic acid molecule are the four sites susceptible to chemical modification, with primary modification methods including esterification, cross-linking, and grafting. The two most commonly used sites for covalent modification of hyaluronic acid are the carboxyl and hydroxyl groups. Currently reported derivatives with clinical application value are primarily new excipients derived from the modification of the hydroxyl and carboxyl groups of hyaluronic acid. 

These derivatives can be selected based on their intended use, with appropriate cross-linking agents chosen to enhance relevant physical properties such as biocompatibility, degradability, in vivo retention time, drug loading capacity, and stability. Hyaluronic acid gels modified with diethyl sulfoxide (DVS) exhibit unique biocompatibility and other properties, solutions using aldehydes as cross-linking agents (hyaluronic acid fluids) exhibit high viscoelasticity, while cross-linking agents with multiple functional groups, such as epoxy compounds, can improve water solubility. Additionally, the reaction between cross-linking agents and the carboxyl groups of hyaluronic acid can produce derivatives, such as esters and amines, which enhance biocompatibility, among other properties [8]. Furthermore, cross-linking reactions can be used to design and prepare functional, intelligent drug carriers, thereby enhancing drug efficacy, improving drug targeting, and reducing adverse effects. Therefore, the use of cross-linking reactions to modify hyaluronic acid not only expands its application scope but also enhances its practical value [9].

3ヒアルロン酸粉末の応用

3.1化粧品への応用

In the early 1980s, the excellent moisturising properties of hyaluronic acid garnered significant attention from the international cosmetics industry. Extensive literature and decades of domestic and international applications have demonstrated that hyaluronic acid can be used in cosmetics such as creams, lotions, masks, beauty serums, toners, lipsticks, foundations, and essences, as well as in products like shampoos, conditioners, mousses, and facial cleansers. For example, Restylane by Swiss company Restylane, Hydrobella moisturising lotion by French company Maybelline, and domestic brands such as Yongfang, Ziranmei, and Lvdanlan [10]. In cosmetics, hyaluronic acid plays a role in moisturising, preventing and repairing skin damage, nourishing and lubricating the skin, and having antibacterial and anti-inflammatory effects. Currently, for the rejuvenation of facial wrinkles, botulinum toxin and skin fillers are the two main non-surgical treatment methods, targeting dynamic and static wrinkles, respectively. Since hyaluronic acid was first used as a skin filler, its advantages and efficacy have gradually gained recognition from both medical professionals and patients, leading to a steady increase in usage. It has broken the dominance of collagen-based products and has ranked first in usage in the United States for five consecutive years [11].

3.2食品への応用

In China, over 98% of hyaluronic acid is primarily used in the pharmaceutical, clinical diagnosis, and cosmetics industries. Hyaluronic acid is still in its infancy in the food sector, with limited reports available. In fact, hyaluronic acid is not only used topically for moisturisation; oral hyaluronic acid can also enhance the body&#水分補給39;s。消化吸収を通じて、ヒアルロン酸は活力と若々しさを高めることができます;肌に潤いを与え、なめらかにし、柔らかく弾力的にします。また、老化を遅らせ、関節炎、動脈硬化、不整脈、脳の萎縮などの症状を予防することができます。ヒアルロン酸配合が増え美顔器や健康の錠剤が販売され、国内にも国際法的にもECM・HyaronなどE日本ヒアルロン酸研究院が作った美速くカプセルをわけあたえNatural-Maxヒアルロン酸カプセルやタブレットpcソース天才製作、国内利用可能な口頭はかない美コラーゲンヒアルロン酸蔓やRui'erの水のカプセル。

3.3临床応用

純粋なヒアルロン酸製剤臨床用途には、液体スプレー、ゲル塗布、フィルムカバレージの3つの形態があります。ヒアルロン酸は眼科や整形外科で広く使用されており、一般外科、耳鼻咽喉科、手の外科など、他の多くの分野にも拡大しています。ヒアルロン酸は、骨と関節の病気の治療に使用され、効果的に関節炎、関節の痛みを緩和し、関節機能を調節します。骨折固定術、関節のこわりつき、腰椎切除術の注射療法においても良好な結果を示しています。術後の組織接着は、手術における大きな課題です。ヒアルロン酸は術後の接着を効果的に防ぎ、接着による合併症や後遺症を大幅に軽減することが、多くの臨床試験で証明されています。ヒアルロン酸は人体や動物の体に含まれる天然成分なので、副作用のない医薬品原料として安全で信頼性があります。そのため、ヒアルロン酸は医療分野で非常に人気の高い新しい生体材料となっています。

Pang Suqiu et al. [12] used hyaluronic acid solution to treat dry eye syndrome, and clinical results indicated that hyaluronic acid has a good therapeutic effect on dry eye disease. Goto et al. [13] administered sodium hyaluronate into the joint cavities of 25 patients with chronic progressive joint diseases, and followed up with clinical symptoms and parameters. The results showed significant improvements in all indicators, with patients'条件改善。luo hongtuら[14]さまざまな甲状腺手術を受けている396人の患者を2つのグループに無作為に分けた。この実験群(214例)は、広頚筋の深部である前頸部筋群までの甲状腺創傷表面にヒアルロン酸注射を受けた。対照群の182人の患者にはヒアルロン酸は投与されなかった。

The results showed that 26 cases of postoperative adhesion occurred in the experimental group, while 41 cases occurred in the control group, with a significant difference between the two groups. Additionally, hyaluronic acid, as an important component of the extracellular matrix, regulates interactions between cells and between cells and the matrix, promoting wound healing and inhibiting abnormal scar formation caused by excessive collagen deposition. Hyaluronic acid also promotes granulation tissue formation, reduces scab area, shortens scab detachment time, and has a promoting effect on burn healing. Jiang Lixia et al. [8] reported that spraying burn patients with hyaluronic acid artificial skin powder resulted in good therapeutic effects and high safety.

3.4薬局でのアプリケーション

3.4.1薬物安定性の改善

Freeze-dried single-chamber liposomes tend to reform into large multi-chamber liposomes, which is detrimental to therapies requiring small particle liposomes. Wang Yuhui [15] reported that by bonding sodium hyaluronic acid to the surface of biodegradable liposomes via hydrogen bonds, the transformation of freeze-dried single-chamber liposomes into large multi-chamber liposomes could be effectively inhibited, thereby stabilising freeze-dried single-chamber liposomes. Peer et al. [16] prepared hyaluronic acid-heparin conjugate gels and bound recombinant human basic fibroblast growth factor-2 (FGF-2) to the heparin end of the hyaluronic acid-heparin conjugate. In vitro analyses indicated that hyaluronic acid-heparin conjugate gels enhance the stability and activity of FGF-2.

3.4.2制御リリース製剤におけるアプリケーション

Hyaluronic acid and its derivatives can serve as sustained-release carriers for various drugs, such as anticancer drugs, anti-inflammatory drugs, and anaesthetics. Hyaluronic acid has diverse application forms as a drug carrier. Chou et al. [17] prepared hyaluronic acid-coated polycyanoacrylate butyl ester nanoparticles (hyaluronic acid-PBCA), which were obtained through a free radical polymerisation reaction of hyaluronic acid monomers and polycyanoacrylate monomers. Using paclitaxel as a model anticancer drug, the encapsulation efficiency of hyaluronic acid-PBCA nanoparticles reached 90%. The tumor cell proliferation inhibitory effect of paclitaxel-loaded hyaluronic acid-PBCA nanoparticles was significantly higher than that of paclitaxel-loaded PBCA nanoparticles and paclitaxel injection. Homma et al. [18] conjugated hyaluronic acid with the anti-inflammatory drug methotrexate using short peptides and linkers to form hyaluronic acid-methotrexate conjugates for the treatment of osteoarthritis, achieving controlled-release of the drug at the site of inflammation and effectively reducing the toxic side effects of methotrexate. Hyaluronic acid hn et al. [19] prepared injectable hyaluronic acid microgel for the controlled release of erythropoietin (EPO). In vivo release experiments showed that EPO was slowly released from the microgel, with plasma EPO concentrations exceeding 0.1 mg/L, which is the minimum concentration required for EPO to exert its effects. This concentration was maintained for 7 days without significant toxic side effects.

Hyaluronic acid and its derivatives as carriers offer unique biocompatibility, rheological properties, and chemical and physical diversity, making them an effective sustained-release system for pharmacologically active molecules. The practical application of hyaluronic acid as a biological carrier combined with various drugs will be a key focus of future research and development.

3.4.3抗がん剤でのアプリケーション

Research has shown that certain solid tumours and metastatic lymphocytes express high levels of hyaluronic acid receptors—CD44—with which hyaluronic acid has a strong affinity. As a targeted carrier for antitumour drugs, hyaluronic acid can bind smaller drug molecules to its network structure or graft drug molecules onto hyaluronic acid-based drug carriers, targeted binding with receptors on the surface of tumour cells, enabling more drug molecules to enter tumour tissue, increasing the absorption and retention time of anticancer drugs in tumours and lymph nodes, thereby enhancing drug efficacy and reducing toxic side effects. Luo et al. [20] esterified hyaluronic acid with paclitaxel to form a bio-targeted prodrug. Fluorescent labelling revealed that the drug could specifically bind to cells, and this binding could be blocked by excess hyaluronic acid and anti-CD44 antibodies but not by chondroitin sulfate. Paclitaxel was released through the hydrolysis of the ester bond. Brown et al. [21] administered 5-fluorouracil and methotrexine containing hyaluronic acid and without hyaluronic acid to nude mice with thymoma via tail vein injection, The results showed that the drug concentrations in the tumour tissue increased by 403% and 106%, respectively.

Hyaluronic acid and its derivatives can be formulated into drug compositions or used as carriers to target and retain different drugs in various parts of the human body. This not only enables drugs to act on more precise target sites, increasing the concentration of therapeutic drugs at the site of action and significantly enhancing therapeutic efficacy, but also avoids drug side effects, providing a more effective approach for disease treatment [22].

3.5生体材料

As a biomaterial, hyaluronic acid possesses advantages such as good biocompatibility and rapid biodegradability. Chen Jianying et al. [23] conducted biocompatibility tests on cross-linked hyaluronic acid gel membranes (CIIA-gel) in terms of in vitro haemolysis, cytotoxicity, acute toxicity, eye irritation, intradermal reaction, sensitisation, and genotoxicity. The results demonstrated that CIIA-gel material exhibits excellent biocompatibility and stable physical and chemical properties. Xiao Rongdong et al. [24] conducted in vivo degradation tests on hyaluronic acid membranes, which conformed to the general process of biodegradation of biomaterials in vivo, with no significant inflammatory reactions and satisfactory tissue compatibility. Fan Hongbin, Hu Yunyu et al. [25] conducted experimental studies on gelatin-chondroitin sulfate-sodium hyaluronate as a tissue engineering cartilage scaffold, demonstrated that gelatin-chondroitin sulfate-sodium hyaluronate porous scaffolds prepared by vacuum drying at 80°C exhibit good pore size, porosity, and compressive load-bearing capacity, and show good compatibility with rabbit bone marrow mesenchymal stem cells (MSCs), making them a novel biomimetic scaffold material for cartilage tissue engineering.

4分析と概要

In recent years, hyaluronic acid has developed rapidly. In 1985, the total global sales of hyaluronic acid in the international market reached 100 million USD, rising to over 200 million USD in 1990. By 2004, the global market size for hyaluronic acid applications was approximately 3 billion USD, and by 2012, it had grown to approximately 4.5 billion USD. Statistical data show that in 2012, the total sales of hyaluronic acid as a single skin filler in the international market reached 1.4 billion US dollars, with the markets for drug cosmetics and skincare products and medical products each accounting for half [26-28].

ヒアルロン酸は新しいタイプの賦形剤として、良好な生体適合性、急速な分解、優れた保湿特性、組織安定性などの利点があります。しかし、中国におけるヒアルロン酸の発達を妨げるいくつかの問題があります。まず、China's production capacity for hyaluronic acid is far from meeting market demand, especially for high-molecular-weight pharmaceutical-grade hyaluronic acid, which must be imported from abroad. Therefore, increasing the molecular weight and production volume of hyaluronic acid is an urgent issue to address.

Second, the variety of hyaluronic acid derivatives is relatively limited, with similar physical and chemical properties, limiting the range of options available and necessitating further research and development. Third, there are no clear grading standards for hyaluronic acid, which is currently classified into food-grade, cosmetic-grade, and pharmaceutical-grade categories based on intended use. The criteria for these classifications are vague, and there is significant overlap between grades, causing significant inconvenience in practical applications. Fourth, when used as a drug carrier, there is no standard method for calculating drug loading capacity, which affects drug content and preparation processes. Fifth, the process of combining hyaluronic acid with other materials to produce biomaterials is still immature, with low production rates and currently at an early stage, requiring further research.

また、収量とquality of hyaluronic acid produced by microbial methods primarily depend on the following factors: the performance of the production strain, the culture medium, the optimisation of fermentation processes, and the control of fermentation and subsequent separation and purification [29-30]. In China, due to limitations in fermentation equipment, processes, and strain selection, the production level and efficiency of hyaluronic acid are relatively low compared to foreign countries, with imports being the primary source, especially for high-purity, high-molecular-weight hyaluronic acid. Due to these limitations, the price of hyaluronic acid in China remains high. However, with the increasing maturity of fermentation technology in China, growing health awareness, and improved understanding of hyaluronic acid, the market for food-grade hyaluronic acid has seen rapid expansion in recent years. In summary, whether for pharmaceutical, cosmetic, or food applications, hyaluronic acid holds vast development potential and demand.

Finally, it is hoped that through the joint efforts of domestic and international scholars, more innovative ideas and applications can be applied to hyaluronic acid research and development, ensuring that the comprehensive development of hyaluronic acid is just around the corner.

参照

[1] bai huiyu, xu jing, li huijun, et al。ヒアルロン酸の調製と応用に関する研究の進展[j]。^「広東化学工業」。広東化学工業(2010年). 2010年11月23日閲覧。

【2】宋雷、王騰飛。ヒアルロン酸研究の現状のレビュー[j]。^『仙台市史』仙台市教育委員会、2012年(平成24年)2月26日。

[3] chen yihan, ye rui, qian yue, et al。ヒアルロン酸の生化学的生産に関する研究の進展[j]。上海応用技術院誌,2012,12(2):1124。

[4] valarie l, bruce a . streptococcus pyogenesおよびstreptococcus equisimilis由来の組み換えヒアルロン酸合成酵素の精製と脂質依存性[j]。^ a b c d e『人事興信録』第4版、274頁。

[5] neuman mg、orua l、coto g、et al。ヒアルロン酸は、in vitroで皮膚細胞におけるエタノール誘導アポトーシスの修復を示す[j]。2010年Clin直し、43(10/11):822。

[6] ozgenel g, et6z a .屈筋修復後の腹膜癒着に対するヒアルロン酸反復注射の効果:予備的ランダム化プラセボ対照臨床試験[j]。2012年・ウルスTravmaだCerrahi Derg、18 (1):11 .

[7] balazs e a, laurent t c . round table discussion: new applications for hyaluronan [a]。laurent t . c . the chemistry, biology, and medical application of hyaluronan and its derivatives [m]。london: portland press, 1998: 325。

【8】江麗霞、王文彬。ヒアルロン酸およびその誘導体の医療への応用[j]。2010年中国日刊手術を受け、14(15):56。

[9] xu xin, shi danping, ye wenxi, et al。架橋ヒアルロン酸誘導体の調製の進展[j]。^ a b c d e f g h『化学工業』、2012年、39頁。

[10]汎宏美。ヒアルロン酸研究の現状の総説[j]。四川省の食品と発酵、2003年、1(8):67。

[11]呉Sufan。ヒアルロン酸の基礎知識と臨床応用[j]。2010年(平成22年)4月1日:ダイヤ改正。

[12] pang suqiu, zhou jinsheng, chen qiushuang, et al。ヒアルロン酸ナトリウムの臨床応用[j]。^『仙台市史』通史編5(通史編4)252頁。

[13] goto m, hanyu t, yoshio t, et al。ヒアルロン酸(si-6601d)の関節内注射により、関節痛と関節液プロスタグランジンe2値が改善:多施設共同臨床試験[j]。clin exp rheumatol, 2001, 19(4): 377。

【14】羅鴻図、楊紹宇。甲状腺手術後の術後癒着に対するヒアルロン酸ナトリウムの予防効果に関する研究[j]。^ a b c d e f『臨床心理学』、2009年、12(5)、313頁。

【15】xiang王禹会。ヒアルロン酸とそのナトリウム塩の医薬品製剤への応用[j]。^「food and medicine」。food and medicine(2011年). 2011年7月8日閲覧。

[16] yang hao, xiong wenshuo, ying guoqing, et al。架橋ヒアルロン酸誘導体の調製と応用[j]。2006年(平成18年)4月5日:ダイヤ改正。

[17] chou w y, ko j y, wang fs, et al。完全な涙を伴わない回旋体カフ病変に対するヒアルロン酸ナトリウム治療の効果:無作為化、二重盲検、プラセボ対照試験[j]。the journal of shoulder and elbow surgery, 2010, 19(4): 557。

[18] homm a, sato h, tamura t, et al。変形性関節症の治療における利益を最大化するためのヒアルロン酸-メトトレキサート複合体の合成と最適化[j]。Bioorganic &汉方薬の化学、2010年、18(3):1062年。

[19] hahn s, kim js, shimoboujit h .エリスロポエチンのコントロールリリース製剤化のための注射型ヒアルロン酸マイクロハイドロゲル[j]。^ a b c d e f『仙台市史』通史編、2006年(平成18年)4月、89頁。

[20] luo y, ziebell m r, prestwich g d .癌細胞を標的としたヒアルロン酸タキソール抗腫瘍バイオコンジュゲート[j]。^ a b cアポロドーロス、2000年(平成12年)2月1日。

[21] brown t j, hatherell e m, falzon j l, et al。ヒト乳房腫瘍異種移植片に対する抗代謝物抗がん剤のヒアルロン酸ターゲット[z]。2005年(平成17年)には、がん化学物質(cancer chemother pharmacol)に登録された。

[22] liu z, wang b .ヒアルロン酸臨床研究における新たな進歩[j]。2006年(平成18年)8月12日:現在地に移転。

[23]陳建英、宋海伯。架橋ヒアルロン酸ゲル膜の調製と生体適合性研究[j]。^ a b c d e f g h『生物工学』、2009年、28頁。

【24】小栄東翁國興。コラーゲン/ヒアルロン酸膜とゼラチンスポンジ足場材料の機械的特性と組織適合性の比較[j]。中国の組織工学研究誌,2012,16(25):1123。

【25】範弘彬、雲羽。組織工学軟骨足場としてのgelatin-chondroitin sulphate-sodium hyaluronateの実験的研究[j]。中国日刊手術を受け05シーズンまで、19(6):473た。

[26] chou cl, li hw, lee sh, et al。変形性膝関節症患者における関節内ヒアルロン酸注射の効果[j]。中国医学学会誌,2008,71(8):411。

[27]李天秀、李天秀、朴tg。ヒアルロン酸-パクリタキセル共役ミセル:合成、特性評価、および抗腫瘍活性[j]。^「bioconjugate chemistry, 2008, 19(6): 1319」。bioconjugate chemistry(2008年). 2008年9月19日閲覧。

[28] benjamin y s o, ranganath s h, lee l y, et al。多形性膠芽腫に対する術後化学療法における制御放出のためのplga発泡体からのパクリタキセル送達[j]。^ a b c d e f g h i(2009年)30頁。

[29] park k, lee m y, kim k s, et al。還元可能なポリエチレンイミンヒアルロン酸結合を有するvegf sirnaによる標的特異的腫瘍治療[j]。^「bioaterials」。biomaterials(2010年). 2019年3月31日閲覧。

[30] sudhir h, yilong f, davis y, et al。マウスの頭蓋内神経膠腫において、薬物動態および治療効果を増強したパクリタキセルを送達するためのサブマイクロナノスケールplgaインプラントの使用[j]。^ a b c d e f g h i(2010年)31頁。